Leerink reiterates AC Immune stock rating on Lilly deal amendment By Investing.com

AC Immune amended its collaboration with Eli Lilly, receiving a CHF10m upfront payment and becoming eligible for >CHF1.7bn in milestone payments plus tiered royalties, and will begin IND-enabling studies in H1 2026. Leerink reiterated an Outperform with a $9 price target (stock at $3.08) and Jefferies maintained a Buy; AC Immune has shown Phase 1 PET tracer data (ACI-19626) for TDP-43 and started a Phase 1 trial of ACI-19764. The amendment validates the Morphomer small-molecule platform and materially de-risks program economics, likely positive for AC Immune shares though programs remain early-stage.

Analysis

The amendment signals a structural derisking for small-molecule intracellular-tau approaches beyond headline payments: it increases the bargaining power and optionality of platform owners that can combine therapeutic and diagnostic assets. A platform that couples an oral small molecule with a proprietary PET tracer materially shortens effective development timelines by enabling biomarker enrichment; trial size and duration can shrink meaningfully (think tens of percent) when you can pre-select pathology-positive patients, which in turn reduces sponsor cash burn and raises deal multiples for early-stage assets.

Second-order supply-chain winners are PET radiochemistry partners and CNS CDMOs capable of GMP small-molecule scale-up; capacity constraints there could become a chokepoint if multiple programs move to IND/Phase 2 around the same window. Principal tail risk is mechanism-level safety or unexpected cognitive signal that forces regulators to demand longer cognitive endpoints — such an outcome would not only reprioritize R&D spend across large pharmas but could also trigger rapid reassessment of milestone accruals and opt-in decisions by partners.

From a portfolio construction perspective this is a classic asymmetric binary: small-cap platform owners capture upside from partner validation and imaging-enabled de-risking, while large-cap sponsors carry broad pipeline diversification but are exposed to reputational/regulatory spillovers. Time horizons matter: option-like upside concentrates over 12–36 months around IND-enabling readouts and early human biomarker data, while systemic regulatory responses play out over multiple years.

Key Decisions for Investors

• Buy ACIU long-dated calls (12–30 month LEAPs). Size as a tactical 0.5–1.5% NAV position: max loss = premium, upside 3x+ if platform milestones or human biomarker readouts validate enrichment strategy. Add 50% on any confirmed PET-driven trial enrichment signal; trim 30–50% on partner opt-in or buyout.
• Core overweight equity tranche in ACIU (1–2% NAV) for investors who can tolerate binary clinical risk. Use a hard stop-loss at -40% absolute to limit downside; target 2–4x within 12–36 months if IND progression and imaging utility translate to partner acceleration.
• Hedge regulatory/class-risk with LLY put spread (9–15 month). Buy a modest OTM put and sell a farther OTM put to fund cost (size 0.25–0.5% NAV). This protects against sector-wide derating should a mechanism-level safety signal reprice large-cap tau exposures; max loss = net premium, payoff concentrated if market re-rates biotech/pharma exposure.
• Pair trade for balanced asymmetric exposure: long ACIU LEAPs (0.75% NAV) + LLY put spread (0.5% NAV). This preserves upside to platform validation while capping portfolio-level downside from a regulatory/class fallout; rebalance after any IND-enabling disclosure or regulatory guidance within 6–18 months.